Increasing objectivity in tissue analysis

We have developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples.

The company holds a broad patent portfolio of three patent families. Lumito’s solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.

Our foundation

A research group in the Division of Atomic Physics and Laser Centre at Lund University proved the advantages of a medical application of upconverting nanoparticles (UCNP). Their research launched what would later become Lumito AB. 

Recent milestones

  • Lumito and Concept Life Sciences join forces to advance tissue analysis in drug discovery
  • Partnership agreement signed, with Truly Labs
  • Signing Paul Waring as Scientific Advisor
  • Letter of intent signed with Katana Labs
  • CEO Sanna Wallenborg started, Aug 2024
  • Scanner system launched, July 2024
  • Kerstin Jakobsson appointed Chair of the Board of Directors, May 2024